CO-CULTURE SIMPLIFIED
Multi-Organ Culture, Simplified.
Scalable Co-Culture for High-Throughput Screening
MicroDUO is a scalable, HTS-compatible microplate platform designed to advance microphysiological systems (MPS) and New Approach Methodologies (NAMs) through co-culture and multi-organ culture in a standard microplate format. Using patented diffusion microchannels connecting adjacent wells, MicroDUO enables reversible intercellular signaling and multi-tissue communication to create more physiologically relevant models for drug discovery, safety and efficacy testing, and predictive toxicology screening.
Unlike traditional co-culture platforms that require specialized equipment or complex operation, MicroDUO initiates co-culture by simply increasing media volume to establish communication between tissues and reverses interaction through media removal. Available in 96-, 384-, and 1536-well ANSI/SLAS formats, MicroDUO integrates seamlessly with existing automation and detection systems—including plate readers and high-content imagers—providing a technically simple and cost-effective solution for scalable multi-tissue assays.
Scalable Assays
96-, 384-, and 1536-well formats for HTS applications
Versatile Platform
Patented design for reversible multi-organ culture
HTS Compatible
Seamlessly integrates
into existing HTS workflows
Flexible Readouts
Supports dual-endpoint analysis across both cell populations
MicroDUO is a scalable, HTS-compatible microplate platform designed to advance microphysiological systems (MPS) and New Approach Methodologies (NAMs) through co-culture and multi-organ culture in a standard microplate format. Using patented diffusion microchannels connecting adjacent wells, MicroDUO enables reversible intercellular signaling and multi-tissue communication to create more physiologically relevant models for drug discovery, safety and efficacy testing, and predictive toxicology screening.
Unlike traditional co-culture platforms that require specialized equipment or complex operation, MicroDUO initiates co-culture by simply increasing media volume to establish communication between tissues and reverses interaction through media removal. Available in 96-, 384-, and 1536-well ANSI/SLAS formats, MicroDUO integrates seamlessly with existing automation and detection systems—including plate readers and high-content imagers—providing a technically simple and cost-effective solution for scalable multi-tissue assays.
Scalable Multi-Organ Culture for High-Throughput Discovery
Co-Founder & Chief Executive Officer
Tony Jimenez is an entrepreneur and biomedical engineer with expertise in developing scalable, human-relevant in vitro systems. He holds a PhD in Biomedical Engineering and has more than 13 years of experience designing microphysiological systems (MPS), organ-on-chip technologies, advanced cell culture platforms, and automated assay workflows for disease modeling, drug discovery, and high-throughput screening (HTS).
Dr. Jimenez is the lead inventor of the MicroDUO technology and has led its design, fabrication, validation, and application development at Onexio. His current work focuses on developing scalable in vitro technologies that advance New Approach Methodologies (NAMs) by increasing physiological relevance and accelerating the adoption of animal-free preclinical models, including next-generation multi-organoid culture platforms.
Co-Founder & Chief Scientific Officer
Brian Johnson’s expertise focuses on bridging the gap between traditional animal models and modern high-throughput screening approaches through the development of human-relevant in vitro systems. Since earning his PhD in Molecular and Environmental Toxicology using mouse models, Brian has accumulated more than 11 years of experience engineering multi-culture and microphysiological systems (MPS) that better recapitulate human physiology in vitro.
At Onexio, Brian led assay design and application development for the MicroDUO platform, including assay workflows that contributed to its advancement through Stage 1 and Stage 2 of the Transform Tox Testing Challenge. In his research laboratory at Michigan State University, his team develops human-derived microphysiological, organotypic, and multi-culture models that reconstruct paracrine and endocrine signaling to support mechanistic studies, drug discovery, chemical screening, and toxicity testing.